Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Reprod Sci ; 28(8): 2144-2146, 2021 08.
Article in English | MEDLINE | ID: covidwho-1384774

ABSTRACT

Although there is no known difference between the clinical manifestations of SARS-CoV-2 in pregnant and non-pregnant women based on the studies published until now, in vitro fertilization (IVF) treatments were suspended during the pandemic due to uncertainties with the suggestions of associated societies. However, we do not have enough data on the exact effects of SARS-CoV-2 on fertility and pregnancy and whether there are damaging effects on IVF outcome. There is no available evidence about the transmission of SARS-CoV-2 by either sexual way or through intrauterine insemination (IUI) or IVF. Up until now, there is no report to document the presence or absence of viral RNA in follicular fluid of SARS-CoV-2-positive women. In this paper, we present a case of oocyte retrieval from a SARS-CoV-2-positive woman and the search for viral RNA by polymerase chain reaction (PCR) in the follicular fluid aspirates.


Subject(s)
COVID-19 Nucleic Acid Testing , COVID-19/diagnosis , Follicular Fluid/virology , Infertility, Female/therapy , Oocyte Retrieval , RNA, Viral/genetics , SARS-CoV-2/genetics , Sperm Injections, Intracytoplasmic , Adult , COVID-19/virology , Female , Humans , Infertility, Female/diagnosis , Infertility, Female/physiopathology , Predictive Value of Tests
2.
Reprod Sci ; 29(2): 620-626, 2022 02.
Article in English | MEDLINE | ID: covidwho-1345228

ABSTRACT

The Pre-IVF Treatment with a GnRH Antagonist in Women with Endometriosis (PREGnant) Trial (clinicaltrials.gov no. NCT04173169) was designed to test the hypothesis that 60-day pre-treatment with an oral GnRH antagonist in women with documented endometriosis and planning an IVF cycle will result in a superior live birth rate to placebo. Eight hundred fourteen women are required from 4 national sites. To determine the feasibility of using an electronic medical record (EMR)-based strategy to recruit 204 participants at the Colorado site, we conducted a survey of women within the UCHealth system. Eligible women, identified using relevant ICD-10 codes, were invited to complete a 6-question survey to assess planned utilization of IVF, potential interest in participation, and whether delays in treatment due to COVID-19 would influence their decision to participate. Of 6354 age-eligible women with an endometriosis diagnosis, 421 had a concurrent infertility diagnosis. After eliminating duplicates, 212 were emailed a survey; 76 (36%) responded, 6 of whom reported no endometriosis diagnosis. Of the remaining 70, 29 (41%) were planning fertility treatment; only 19 planned IVF. All 19 expressed interest in participation. COVID-19 delays in treatment were not considered as a factor affecting participation by 8/19; the remaining 11 felt that it would "somewhat" affect their decision. None reported that they would not consider participation because of COVID-19. EMR-based recruitment for an endometriosis clinical trial is feasible although the overall yield of participants is low. Delays in treatment due to COVID-19 did not appear to overly influence potential recruitment.


Subject(s)
COVID-19 , Endometriosis/therapy , Fertility Agents, Female/therapeutic use , Fertilization in Vitro , Health Knowledge, Attitudes, Practice , Hormone Antagonists/therapeutic use , Infertility, Female/therapy , Patient Selection , Research Subjects/psychology , Adolescent , Adult , Choice Behavior , Double-Blind Method , Electronic Health Records , Endometriosis/diagnosis , Endometriosis/physiopathology , Female , Fertility Agents, Female/adverse effects , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Hormone Antagonists/adverse effects , Humans , Infertility, Female/diagnosis , Infertility, Female/physiopathology , Live Birth , Pregnancy , Pregnancy Rate , Treatment Outcome , United States , Young Adult
3.
Fertil Steril ; 113(6): 1140-1149, 2020 06.
Article in English | MEDLINE | ID: covidwho-457110

ABSTRACT

OBJECTIVE: To summarize current understanding of the effects of novel and prior coronaviruses on human reproduction, specifically male and female gametes, and in pregnancy. DESIGN: Review of English publications in PubMed and Embase to April 6, 2020. METHOD(S): Articles were screened for reports including coronavirus, reproduction, pathophysiology, and pregnancy. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Reproductive outcomes, effects on gametes, pregnancy outcomes, and neonatal complications. RESULT(S): Seventy-nine reports formed the basis of the review. Coronavirus binding to cells involves the S1 domain of the spike protein to receptors present in reproductive tissues, including angiotensin-converting enzyme-2 (ACE2), CD26, Ezrin, and cyclophilins. Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) may cause severe orchitis leading to germ cell destruction in males. Reports indicate decreased sperm concentration and motility for 72-90 days following Coronavirus Disease 2019 (COVID-19) infection. Gonadotropin-dependent expression of ACE2 was found in human ovaries, but it is unclear whether SARS-Coronavirus 2 (CoV-2) adversely affects female gametogenesis. Evidence suggests that COVID-19 infection has a lower maternal case fatality rate than SARS or Middle East respiratory syndrome (MERS), but anecdotal reports suggest that infected, asymptomatic women may develop respiratory symptoms postpartum. Coronavirus Disease 2019 infections in pregnancy are associated with preterm delivery. Postpartum neonatal transmission from mother to child has been reported. CONCLUSION(S): Coronavirus Disease 2019 infection may affect adversely some pregnant women and their offspring. Additional studies are needed to assess effects of SARS-CoV-2 infection on male and female fertility.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/virology , Infertility, Female/virology , Infertility, Male/virology , Orchitis/virology , Pneumonia, Viral/virology , Reproduction , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Female , Fertility , Host-Pathogen Interactions , Humans , Infertility, Female/diagnosis , Infertility, Female/physiopathology , Infertility, Male/diagnosis , Infertility, Male/physiopathology , Male , Orchitis/diagnosis , Orchitis/physiopathology , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Pregnancy , Pregnancy Complications, Infectious/physiopathology , Pregnancy Complications, Infectious/virology , Pregnancy Outcome , Risk Assessment , Risk Factors , SARS-CoV-2 , Sperm Count , Sperm Motility
SELECTION OF CITATIONS
SEARCH DETAIL